SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Aventus Network

Aventus Network ($AVT) is generating significant community interest following the formal incorporation of its DAO in the UAE and the appointment of a strategic advisor to bolster its regional presence. Traders are actively discussing its potential for a major breakout, emphasizing its enterprise-grade technology, Polkadot integration, and current low market capitalization as indicators of an undervalued asset.

"What's Updog?" is a Community Led token.

UpDog

UPDOG CRYPTO is trending as its engaged community actively embraces the "What's UpDog?" meme, fueling bullish sentiment and highlighting its long-term presence on Solana with locked liquidity and a listing on the Jupiter Strict List.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is surging as the community eagerly awaits imminent Phase 3 REGAL trial results, fueling strong conviction around GPS immunotherapy's potential for "curative" outcomes in AML. Investors are overwhelmingly bullish, dismissing persistent bearish takes from some while anticipating a significant short squeeze and potential for substantial buyout offers for its promising pipeline.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending with high anticipation for its R2 launch event, propelled by a recent analyst upgrade and the strong performance of its software division, as the community actively debates the stock's future potential amid rising energy costs boosting EV adoption.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is rallying as market sentiment interprets recent statements on the Mideast conflict as a sign of de-escalation, sparking a 'Trump pump' and optimistic price targets among bulls, while skeptics warn of market manipulation, rising oil prices, and continued geopolitical uncertainty.

Kohl's Corp. engages in the operation of family-oriented department stores. Its business line includes apparel, footwear, and accessories for women, men, and children, home products, beauty products, and accessories. The stores generally carry a consistent merchandise assortment with some differences attributable to regional preferences. The company was founded in 1962 and is headquartered in Menomonee Falls, WI.

Kohl`s Corp.

Kohl's Corp

Kohl's is a hot topic after its recent earnings showed a beat on Q4 results but presented a cautious outlook for the coming fiscal year, fueling mixed sentiment. While many in the community are debating short squeeze potential and highlighting the company's substantial real estate assets, others are concerned about soft sales trends and the broader challenging retail landscape.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

BioNTech is trending as its robust oncology pipeline delivers significant news, including positive Phase 3 data for a breast cancer drug and promising lung cancer therapy results, which has garnered a Goldman Sachs upgrade and shifted community focus towards its potential beyond COVID-19 vaccines.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is actively discussed following its proposed convertible senior notes offering, which raises community questions about management's strategy amid persistent buyout rumors and growing optimism for Casgevy's commercial ramp-up and positive early data from its zugo-cel program, including a new Eli Lilly partnership.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is experiencing intense community debate ahead of its earnings report, as investors weigh significant debt-fueled AI infrastructure spending and recent layoff rumors against its cloud growth potential, further complicated by conflicting reports surrounding a major OpenAI data center project.

AT&T, Inc. is a holding company, which engages in the provision of telecommunications and technology services. It operates through the Communications and Latin America segments. The Communications segment offers wireless, wireline telecom, and broadband services to businesses and consumers located in the US and businesses globally. The Latin America segment provides wireless services and equipment in Mexico. The company was founded in 1983 and is headquartered in Dallas, TX.

AT&T, Inc.

AT&T Inc

AT&T is trending due to its aggressive investments in U.S. connectivity, fiber, and AI infrastructure, coupled with a strong earnings report, positive long-term outlook, and a substantial share buyback program. The community is actively debating whether these strategic moves position it as a compelling value and dividend play, despite ongoing competitive pressures in the telecom sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Alnylam Pharmaceuticals, Inc. $ALNY Holdings Raised by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. lifted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 98.3% during the 3rd quarter, according to the company in its most recent...

First Trust Advisors LP Sells 41,434 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

First Trust Advisors LP trimmed its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 16.5% in the third quarter, according to the company in its most recent Form 13F filing...

12,658 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Purchased by Fieldview Capital Management LLC

Fieldview Capital Management LLC acquired a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the 3rd quarter, according to the company in its most recent disclosure...

Victory Capital Management Inc. Increases Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Victory Capital Management Inc. boosted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 15.4% during the 3rd quarter, according to its most recent 13F filing with...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the twenty-eight ratings firms that are covering the firm...

<ul class="summary-bullets"><li>Under the deal, Tenaya Therapeutics will validate up to 15 gene targets and receive as much as $1.13 billion in development and commercial milestone payments from Alnylam.</li><li>Alnylam will be responsible for all development and commercialization activities of therapeutics associated with the identified gene targets, the companies said.</li></ul> Shares of Tenaya Therapeutics, Inc. (TNYA) pulled back after hours after a significant rally during the regular session on Thursday after the company said that it has entered into a research collaboration deal with Alnylam Pharmaceuticals (ALNY) to potentially develop drugs for cardiovascular disease.TNYA shares pulled back 5% in extended hours of trading after closing up 41% in the regular session.<h2 class="st-heading-2">Deal For Heart Drugs</h2>Under the deal, Tenaya Therapeutics will validate up to 15 gene targets and receive as much as $1.13 billion in development and commercial milestone payments from Alnylam if all the targets lead to approved therapies for cardiovascular disease. Tenaya will receive up to $10 million in the form of an upfront payment, the company said.“By combining our modality agnostic target identification and validation capabilities with Alnylam’s leadership in RNA interference therapeutics, we have an opportunity to advance candidates for novel genetic targets with the potential to create transformational medicines for patients with heart disease,” Tenaya CEO Faraz Ali said.Alnylam will be responsible for all development and commercialization activities of therapeutics associated with the identified gene targets, the companies said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around TNYA stock rose from ‘bearish’ to ‘bullish’ over the past 24 hours, while message volume increased from ‘normal’ to ‘high’ levels.A Stocktwits user said that they are awaiting positive data for Tenaya’s TN401 this year with “no curative competition.” TN-401 is a gene therapy for a heart condition called PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC).<stembedurl>https://www.stocktwits.com/Raumerica/message/646689743</stembedurl>Another said that the best part about the deal is that Tenaya will just be researching fifteen additional targets for future commercialisation while still owning all of its own drugs.<stembedurl>https://www.stocktwits.com/Raumerica/message/646703938</stembedurl><a href="https://stocktwits.com/symbol/TNYA">TNYA stock</a> has gained 78% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/owlet-stock-is-down-26-percent-after-hours-after-it-reports-q4-2025-earnings/cZdX4n1RI36">Owlet Stock Is Down 26% After Hours – How Did The Company’s Q4 Results Fare?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

TNYA Pulls Back After Hours Following Significant $1.13B Deal-Spurred Rally

Tenaya shares closed 40% higher in the regular trading session after it entered into a research collaboration deal with Alnylam Pharmaceuticals. 

Equity

Tenaya shares closed 40% higher in the regular trading session after it entered into a research collaboration deal with Alnylam Pharmaceuticals. 


Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells $562,592.22 in Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) EVP Pushkal Garg sold 1,717 shares of the firm's stock in a transaction on Monday, March 2nd. The shares were sold at an average price of...

Focus Partners Advisor Solutions LLC Boosts Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY

Focus Partners Advisor Solutions LLC increased its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 533.0% during the third quarter, according to the company in its...

Pushkal Garg Sells 1,775 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) EVP Pushkal Garg sold 1,775 shares of the business's stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at...

Jeffrey Poulton Sells 2,206 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) EVP Jeffrey Poulton sold 2,206 shares of the company's stock in a transaction dated Monday, March 2nd. The shares were sold at an average...

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

ALNY
Alnylam Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ALNY News

ALNYAlnylam Pharmaceuticals Inc